BIOGEN for BIOGEN
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
IP/Trade TRIPS Waiver
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
Health Issues HCR
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis H.R.19, Lower Costs, More Cures Act of 2021 Discussions regarding FDA approval of Aduhelm
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR New | — |
| JONATHAN CAUSEY | — |
| AMY DEMSKE | — |
| JOHN RAYMOND GIBSON | — |
| SUSAN KORNETSKY | — |
| CAROLINE TUCKER | — |
Medicare/Medicaid MMM
Discussions regarding Medicaid 340B drug discount program Reducing Out-of-Pocket Costs for Biosimilars in Medicare Part B
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR New | — |
| AMY DEMSKE | — |
| TYLER HANSON New | Office of Rep. McNerney 6/2015 - 2/2017 |
| CAROLINE TUCKER | — |
Budget/Appropriations BUD
S.Con.Res.14, FY 2022 Congressional Budget
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
Pharmacy PHA
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.